Dossier assessment
Evinacumab (homozygous familial hypercholesterolaemia, 5 to 11 years) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Evinacumab (homozygous familial hypercholesterolaemia, 5 to 11 years) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Evinacumab (homozygous familial hypercholesterolaemia, 5 to 11 years) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Children aged 5 to 11 years with homozygous familial hypercholesterolaemia in whom dietary and drug options for lipid lowering have been exhausted
Added benefit not proven
Project details
- Project no.
- A24-06
- Commission
- Commission awarded on 10.01.2024 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A24-06_en
Connected Projects
-
Dossier assessment
Evinacumab (homozygous familial hypercholesterolaemia; adults and adolescents >= 12 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed